Search Medical Condition
Please enter condition
Please choose location from dropdown

Oberhausen, Germany Clinical Trials

A listing of Oberhausen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (396) clinical trials

A Study of ASP8302 in Participants With Underactive Bladder

The study will comprise a screening visit, followed by a treatment period and a 2-week follow-up period, in total 8 weeks. Participants will visit the clinic at screening (visit 1) and every 2 weeks (visit 2, 3, 4, and 5). During the course of the study assessments will be performed ...

Phase

6.11 miles

Learn More »

International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)

Indication First-line treatment of high grade gliomas, diffuse intrinsic pontine glioma, and gliomatosis cerebri in paediatric patients < 18 years of age. Background Based on published results regarding the potential therapeutic benefit of adult and pediatric high grade glioma patients receiving either the histone deacetylase (HDAC) inhibitor valproic acid (VPA; ...

Phase

6.11 miles

Learn More »

Pilot Study to Asses the Function and Patency of Polyester-Coated Composite Bypasses From Autologous Varicose Veins

The ProVena trial is a non-randomised multi-centre trial, aiming to assess the suitability of the ProVena vein support. Currently, autologous veins are preferred to prosthetic grafts (Klinkert et al. 2004), but they are not considered to be suitable if they are varicose. Some early data indicate that these veins can ...

Phase N/A

6.55 miles

Learn More »

A Study of the Anti-PD1 Antibody PDR001 in Combination With Dabrafenib and Trametinib in Advanced Melanoma

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma

Phase

6.74 miles

Learn More »

Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy

Real-Life Efficacy and Safety of Nivolumab monotherapy or in combination with Ipilimumab in patients with Advanced (Unresectable or Metastatic) Melanoma and in patients with adjuvant Nivolumab therapy

Phase N/A

6.74 miles

Learn More »

Efficacy Safety and Tolerability of Eziclen /Izinova Versus Klean-prep on Bowel Cleansing in Adolescents Undergoing Colonoscopy

The purpose of the protocol is to demonstrate that Eziclen/Izinova, an osmotic sulphate-based laxative preparation given on the day before colonoscopy has non-inferior efficacy to Klean-Prep (polyethylene glycol (PEG)-electrolytes) on colon cleansing in adolescents aged 12 to 17 years (inclusive) with a body weight >40 kg, scheduled to undergo a ...

Phase

6.74 miles

Learn More »

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer.

Phase

6.74 miles

Learn More »

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments

Phase

6.74 miles

Learn More »

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every 2, 3, or 4 weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors. In the initial ...

Phase

6.74 miles

Learn More »

Open-Label Study to Evaluate Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Refractory or Intolerant Fungal Diseases

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of SCY-078 in patients 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment. Patients will be treated ...

Phase

6.74 miles

Learn More »